期刊文献+

SLE干扰素调节因子-1基因表达及泌乳素的研究 被引量:1

Expression of interferon regulatory factor 1 in patients with systemic lupus erythematosus and the influence of prolactin upon it
原文传递
导出
摘要 目的探讨SLE患者中干扰素调节因子-1(IRF-1)基因的表达情况及泌乳素(PRL)对其干预作用。方法电化学发光仪检测30例SLE患者与20例正常人对照组在清晨静息状态下的血清PRL水平,按密度梯度离心法分离、培养外周血PBMC,将样本分为SLE患者组、正常人对照组、正常PRL的SLE患者组+重组人泌乳素(rhPRL)和正常人对照组+rhPRL等4组。应用RT—PCR结合凝胶图象扫描技术检测IRF-1基因的表达情况:结果SLE患者组与正常人对照组IRF-1基因表达的相对值分别为0.89±0.21和0.78±0.18,两组比较,差异有统计学意义(P=0.026),高PRL的SLE患者组为1.06±0.26,显著高于正常PRL的SLE患者组的0.82±0.21(P=0.005),而正常PRL的SLE患者组与正常人对照组间差异无统计学意义(P=0.514)。经rhPRL刺激后,正常PRL的SLE患者IRF-1基因表达的相对值为0.99±0.22,显著高于rhPRL刺激前(P=0.036),而正常人对照组在刺激前后差异无统计学意义。结论SLE中存在IRF-1基因的表达异常,高PRL水平可能是导致IRF-1基因异常表达的原因之一。 Objective To study the expression of interferon regulatory factor 1 (IRF-1) in patients with systemic lupus erythematosus (SLE) and the influence of prolactin (PRL) upon it. Methods The level of serum PRL in quiescent condition was examined by electrochemiluminescence-meter in 30 patients with SLE and 20 healthy controls. Peripheral blood mononuclear ceils i PBMC) were separated from all the subjects by gradient centrifugation density, and cultured PRL (rhPRL) for 24 hours. The expression of IRF-1 with or without the presence of recombinant human gene in cultured PBMC was detected by reverse transcriptase-PCR (RT-PCR) with gel image scanning. Results The relative value of IRF-1 gene expression was significantly higher in SLE patients than in normal controls (0.89 ± 0.21 vs 0.78 ± 0.18, P = 0.026), and in SLE patients with high PRL than in those with normal PRL (1.06 ± 0.26 vs 0.82 ± 0.21, P=0.005). However, there was no significant difference between SLE patients with normal PRL and healthy controls in regard to the expression of IRF-1 gene (P = 0.514). The stimulation with rhRPL significantly elevated the relative expression of IRF-1 gene in SLE patients with normal PRL (0.99 ± 0.22 vs 0.82 ± 0.21, P = 0.036), but had no obvious effect on that in the normal controls. Conclusion The study reveals a high expression of IRF-1 gene in SLE patients, which may be related to the high level of PRL.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2008年第9期579-581,共3页 Chinese Journal of Dermatology
基金 广东省医学科研课题(A2000379)
关键词 红斑狼疮 系统性 催乳素 干扰素调节因子-1 Lupus erythematosus, systemic Prolactin Interferon regulatory factor 1
  • 相关文献

参考文献8

  • 1Fujita T, Kimura Y, Miyamoto M, et al. Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature, 1989, 337(6204): 270-272.
  • 2陶金辉,李向培,厉小梅,汪国生,钱龙,王玮.IFN-γ在系统性红斑狼疮发病中的作用和临床意义[J].疾病控制杂志,2005,9(3):278-280. 被引量:7
  • 3李锋,冯树芳,徐金华,吴厚生.催乳素对系统性红斑狼疮患者单一核细胞产生IgG和抗dsDNA抗体的影响[J].中华皮肤科杂志,2004,37(1):32-34. 被引量:6
  • 4Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev, 2000, 80(4): 1523-1631.
  • 5Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev, 2000, 11(3): 199-207.
  • 6Harada H, Takahashi E, ltoh S, et al. Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system. Mol Cell Biol, 1994, 14(2): 1500-1509.
  • 7Lohoff M, Mak TW. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol, 2005, 5 (2): 125- 135.
  • 8Goffin V, Binart N, Clement-Lacroix P, et al. From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models. Genet Anal, 1999, 15(3-5 ): 189-201.

二级参考文献15

  • 1夏金华,吴厚生.天然DNA和细胞因子对系统性红斑狼疮患者淋巴细胞体外分泌抗双链DNA抗体的影响[J].上海医科大学学报,1994,21(2):109-112. 被引量:13
  • 2Hayashi T, et al. Reduction of .serum interferon (IFN)-garnma concentration and lupus development in NZB×NZWF(1)mice by lactic dehydrogenase virus infection [J]. J Comp Pathol, 2001,125(4):285-291.
  • 3Horwitz DA, Gray JD, Behrendsen SC, et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus [J].Arthritis Rheum, 1998,41(5):838-844.
  • 4Slavikova M, Sehrneixser H, Kontsekova E, el al. Incidence of autoantibodies against type I and type ll interferons in a cohort of systemic lupus erythernatosus patients in Slovakia [J]. J Interferon Cytokine Res, 2003,23(3):143-147.
  • 5Baechler EC, Batliwalla FM, Ortmann WA, et al. Interferoninducible gene expression signature in peripheral blood cells of patients with .severe lupus [J]. Proc Natl Acad Sci USA, 2003,100(5):2610-2615.
  • 6Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on Prognosis Studies in SLE [J]. Arthritis Rheum, 1992,35(6):630-640.
  • 7Machold KP, Smolen JS. Interferon-gamma induced exacerbation of systemic lupus erythematosus [J]. J Rheumatol, 1990,17(6):831-832.
  • 8Wandl UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative dimrders [J]. Clin Immunol Immunopathol, 1992,68(1):70-74.
  • 9Ozmen L, Roman D, Fountoulakis M, et al. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis[J]. Eur J Immunol, 1995,25(1):6-12.
  • 10Balomenos D, Rumold R, Theofilopoulos AN, et al. Interferongamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice [J]. J Clin Invest, 1998,101(2):364-371.

共引文献11

同被引文献14

  • 1吴元胜,范瑞强,陈达灿,禤国维.基因芯片技术分析系统性红斑狼疮患者外周血白细胞基因表达谱的初步研究[J].第一军医大学学报,2005,25(8):929-934. 被引量:5
  • 2Ptacek T,Li X,Kelley JM,et al.Copy number variants in genetic susceptibility and severity of systemic lupus erythematosus.Cytogenet Genome Res,2008,123(1-4):142-147.
  • 3Cheng RY,Birely LA,Lum NL,et al.Expressions of hepatic genes,especially IGF-binding protein-1,correlating with serum corticosterone in microarray analysis.J Mol Endocrinol,2004,32 (1):257-278.
  • 4Wang JC,Derynck MK,Nonaka DF,et al.Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes.Proc Natl Acad Sci U S A,2004,101(44):15603-15608.
  • 5Gladkevich A,Nelemans SA,Kauffman HF,et al.Microarray profiling of lymphocytes in internal diseases with an altered immune response:potential and methodology.Mediators Inflamm,2005,(6):317-330.
  • 6Esposito P,Balletta MM,Procino A,et al.Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis.Lupus,2009,18(14):1329-1330.
  • 7Harigai M,Kawamoto M,Hara M,et al.Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B.J Immunol,2008,181 (3):2211-2219.
  • 8Tsukamoto H,Horiuchi T.Clinical aspects of the complement system.Rinsho Byori,2006,54(7):757-762.
  • 9Jia EZ,Wang J,Yang ZJ,et al.Association of the mutation for the human carboxypeptidase E gene exon 4 with the severity of coronary artery atherosclerosis.Mol Biol Rep,2009,36(2):245-254.
  • 10Herberg JA,Beck S,Trowsdale J,et al.TAPASIN,DAXX,RGL2,HKE2 and four new genes (BING 1,3 to 5) form a dense cluster at the centromeric end of the MHC.J Mol Biol,1998,277(4):839-857.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部